Cannabinol

Cronos Group Reports 2023 Fourth Quarter and Full-Year Results¹

Retrieved on: 
Thursday, February 29, 2024

In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.

Key Points: 
  • In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.
  • Cronos GrowCo reported to the Company preliminary unaudited net revenue to licensed producers excluding sales to the Company in the fourth quarter and full-year 2023 of approximately $6.6 million and $19.6 million, respectively.
  • In addition to principal repayment, Cronos also received approximately $10.3 million in interest payments from GrowCo in 2023, resulting in a total of approximately $15.9 million in cash payments to Cronos in 2023.
  • ET to discuss 2023 Fourth Quarter and Full-Year business results.

Pervasip Announces Financial Results for Fiscal Year 2023

Retrieved on: 
Thursday, February 29, 2024

SEATTLE, WA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2023.

Key Points: 
  • SEATTLE, WA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2023.
  • Operating Loss for the year ending November 30, 2023 totaled ($460,037), compared to an operating loss of $2,422,916 during the same period in 2022.
  • Cashflow for the year ending November 30, 2023 totaled $409,507, compared to negative cashflow of ($798,033) during the same period in 2022.
  • Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.

New Farm Bill-Compliant CBD and Hemp Seed Payment Gateways Now Available

Retrieved on: 
Wednesday, January 17, 2024

With these new payment processing options, American hemp and CBD businesses can showcase the quality and potential of their seeds.

Key Points: 
  • With these new payment processing options, American hemp and CBD businesses can showcase the quality and potential of their seeds.
  • Organic Payment Gateways allows businesses to efficiently sell their hemp and CBD products by providing hassle-free online payment processing.
  • Organic Payment Gateways provides specialized, user-friendly payment gateways tailored to CBD and hemp seed businesses' unique needs.
  • Website owners in the CBD and hemp seed industries can now experience the convenience and flexibility of the new payment acceptance options offered by Organic Payment Gateways.

Healthcare Industry Veteran Donald M. Casey Jr. Joins Board of Directors at Cannabinoid Biotech Leader FloraWorks

Retrieved on: 
Thursday, January 4, 2024

Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc. , a leading cannabinoid biotech company, announced the appointment of Donald M. Casey Jr. as Board Director.

Key Points: 
  • Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc. , a leading cannabinoid biotech company, announced the appointment of Donald M. Casey Jr. as Board Director.
  • Casey brings over 30 years of global healthcare experience to the FloraWorks board, with an outstanding track record of identifying and commercializing medical innovations.
  • "Casey is a proven leader in healthcare operations and will be an integral perspective on our board of directors," said Alleh Lindquist , CEO and Co-Founder of FloraWorks.
  • This study marks the first cannabinoid to be clinically validated to promote better sleep.

Cannabinol (CAS 521-35-7) Global Market Research Report 2023: Applications, Manufacturing Methods, Patents, Pricing and Major End-Use Sectors - ResearchAndMarkets.com

Retrieved on: 
Monday, November 20, 2023

The "Cannabinol (CAS 521-35-7) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabinol (CAS 521-35-7) Global Market Research Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Cannabinol.
  • The Cannabinol global market report offers a comprehensive overview of Cannabinol, covering various key points to provide valuable insights for businesses and stakeholders.
  • In summary, the Cannabinol global market report offers a comprehensive and structured approach to understanding Cannabinol, making it an invaluable resource for businesses and stakeholders operating in this dynamic market.

Introducing Rare Cannabinoid Company's Latest Innovation: THC + CBN Sleep Gummies for a Restful Night's Sleep

Retrieved on: 
Wednesday, November 22, 2023

HONOLULU, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company, a leading provider of premium hemp-infused products, is thrilled to announce the launch of their newest product, THC + CBN Sleep Gummies. Crafted with care and designed to promote a restful night's sleep, these gummies are set to revolutionize the way people experience CBN products.

Key Points: 
  • HONOLULU, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company, a leading provider of premium hemp-infused products, is thrilled to announce the launch of their newest product, THC + CBN Sleep Gummies .
  • THC + CBN Sleep Gummies offer a natural and effective option for those seeking a better night's sleep.
  • Legal Delta-9-THC Gummies: The Delta-9-THC in THC + CBN Sleep Gummies comes in a full spectrum oil that is naturally extracted from legal U.S. hemp plants.
  • They are also releasing THC + CBG Relief Gummies and THC + THCV Uplift Gummies to add to their growing THC Gummies line.

Wyld Introduces New Boysenberry Sleep Gummies

Retrieved on: 
Tuesday, November 14, 2023

CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.

Key Points: 
  • CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.
  • The boysenberry gummy is Wyld's first to include three cannabinoids – THC, CBD (cannabidiol), and CBN (cannabinol) – as well as botanical terpenes.
  • This addition to Wyld's sleep collection joins their Elderberry 2:1 THC:CBN gummy, which is the bestselling cannabis edible in the country according to BDSA data.
  • Wyld's Boysenberry Indica-enhanced gummies is available in the U.S.

Cronos Group Reports 2023 Third Quarter Results

Retrieved on: 
Wednesday, November 8, 2023

Furthermore, the weakened Canadian dollar and New Israeli Shekel against the U.S. dollar during the period adversely impacted results.

Key Points: 
  • Furthermore, the weakened Canadian dollar and New Israeli Shekel against the U.S. dollar during the period adversely impacted results.
  • Cronos GrowCo reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $6.2 million in the third quarter of 2023.
  • In addition to principal repayment, Cronos also received $1.2 million in interest payments from GrowCo, totaling approximately $2.3 million in cash payments to Cronos in Q3 2023.
  • ET to discuss 2023 Third Quarter business results.

PAX Debuts Novel, Science-Backed Product for Better Sleep

Retrieved on: 
Tuesday, November 7, 2023

PAX , a leading global cannabis brand, today announced the launch of Sleep by PAX, a first-of-its-kind, science-driven inhalable pod formula for the PAX Era platform.

Key Points: 
  • PAX , a leading global cannabis brand, today announced the launch of Sleep by PAX, a first-of-its-kind, science-driven inhalable pod formula for the PAX Era platform.
  • Sleep by PAX leverages a unique blend of cannabinoids and terpenes, developed to help consumers get to sleep faster, improve their sleep quality and ultimately get more restorative sleep.
  • Many Americans are sleep-deprived, which is having a significant impact on health and wellbeing,” said Brian Witlin, VP of Product Development at PAX.
  • Sleep by PAX is now available in a 1G pod format in Colorado starting at $40 and in Massachusetts starting at $60.

How can I get some sleep? Which treatments actually work?

Retrieved on: 
Thursday, October 26, 2023

This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.

Key Points: 
  • This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.
  • Do these sleep problems make you feel fatigued, strung-out, or exhausted during the day?
  • Read more:
    A short history of insomnia and how we became obsessed with sleep

What not to do


These probably won’t help:
spending more time in bed often results in more time spent awake in bed, which can make insomnia patterns worse
drinking coffee and taking naps might help get you through the day. But caffeine stays in the system for many hours, and can disrupt our sleep if you drink too much of it, especially after about 2pm. If naps last for more than 30 minutes, or occur after about 4pm, this can reduce your “sleep debt”, and can make it more difficult to fall asleep in the evening
drinking alcohol might help you fall asleep quicker, but can cause more frequent awakenings, change how long you sleep, change the time spent in different “stages” of sleep, and reduce the overall quality of sleep. Therefore, it is not recommended as a sleep aid.

Read more:
Why do I fall asleep on the sofa but am wide awake when I get to bed?

What to do next?

  • So, the next stage is a type of non-drug therapy known as cognitive behavioural therapy for insomnia (or CBTi for short).
  • It involves education about sleep, and offers psychological and behavioural treatments that address the underlying causes of long-term insomnia.
  • Some GPs are trained to offer CBTi, but it’s more usual for specialist sleep psychologists to offer it.
  • But many psychologists will also charge a gap fee above the Medicare subsidy, making access to CBTi a challenge for some.

What if that doesn’t work?

  • Some lifestyle and work factors, such as shift-work, might also require management by a specialist sleep doctor.
  • Read more:
    Counting the wrong sheep: why trouble sleeping is about more than just individual lifestyles and habits

What about sleeping pills?

  • Sleeping pills are not the recommended first-line way to manage insomnia.
  • Read more:
    Some reasons why you should avoid sleeping pills

Are there new treatments? How about medicinal cannabis?


Two newer drugs, known as “orexin receptor antagonists”, are available in Australia (suvorexant and lemborexant). These block the wake-promoting pathways in the brain. Early data suggests they are effective in improving sleep, and have lower risk of potential side-effects, tolerance and dependence compared with earlier medicines. However, we don’t know if they work or are safe over the long term.

  • Medicinal cannabis has only in recent years been studied as a treatment for insomnia.
  • In an Australian survey, more than half of people using medicinal cannabis said they used it to treat insomnia.

What now?

  • Your GP can help identify and manage these.
  • Your GP can also help you access other treatments if your insomnia is more long term.
  • Dr Sweetman reports previous research funding and/or consultancy work for; the National Health and Medical Research Council, The Hospital Research Foundation, Flinders University, Flinders Foundation, ResMed, Philips, Cerebra, Re-Time, and Australian Doctor.
  • Nicole Grivell is involved in the Australasian Sleep Association as a co-chair of the Primary Care Council and as a member of the Conference Committee.
  • She has previously received PhD funding from the Flinders Foundation in the form of a Nick Antic Sleep Research PhD Scholarship.